Vaccizone to Play an Active Role in the Vaccine of Corona virus Receives Investment from Keiretsu Forum Turkey
Vaccizone, operating in the fields of medicine, vaccine development and bioinformatics against all kinds of diseases, especially cancer and infectious diseases for humans and animals, is preparing to open up to the whole world by receiving investment from Keiretsu Forum Turkey angel investors for its ASC microsphere antigen transport technology patented in four regions of the world including USA, Europe, China and Japan.
Vaccizone, established in 2020 and operates in the fields of drug and vaccine development, pharmacology, biotechnology, genetics, genomics, computer software and bioinformatics against all kinds of diseases, especially cancer and infectious diseases for humans and animals, received investment from angel investors of Keiretsu Forum Turkey for its ASC microsphere antigen transport technology, took 15 years to develop and patented in four regions of the world, the USA, Europe, China and Japan. Vaccizone received Turkey’s first triadic patent in the field of biotechnology with the registration of its patent.
Stating that they set out with the support of Keiretsu Forum angel investor Dr. Alper Türken in 2019, Vaccizone Founder Prof. Dr. Nesrin Özören said “With the SARS-COV 2 (COVID-19) vaccine we are developing, our technology will have proven itself. With this success, we plan to develop strategic partnerships with the leading manufacturers of the sector within the framework of the diseases we have targeted. We are about to reach the Phase-I of the Covid-19 vaccine development program. We believe that we will play an active role in ending the pandemic, thanks to vaccines that can be stored at room temperature, which is one of the most obvious advantages of our technology. We are in the preclinical phase of melanoma immune therapy studies. We are also working on a vaccine project for the sustainable/organic livestock sector”.
Özören stated that their goal is to achieve their full financial independence by performing a public offering on NASDAQ in a 3-5-year term and to become a leading biotechnology brand originating from Turkey that can compete in the international arena. Özören added that with the investment they received from Kereitsu Forum Turkey angel investors, they believe that Vaccizone’s technology will make a significant difference, especially in geographies such as Asia, Africa and South America where access to the cold chain is limited.